TipRanks on MSN
Delcath Systems announces publication of CHEMOSAT study
Delcath Systems (DCTH) announced the publication of a retrospective study by leading interventional radiologists and oncologists from Asklepios ...
For patients with metastatic uveal melanoma, what are the treatment options? Marlana M. Orloff, M.D.: Metastatic uveal melanoma is unique in that when patients recur, close to 90% or more recur in ...
Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...
ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma. Background: Geographical differences in the management of primary UM, surveillance for recurrence, ...
Marlana M. Orloff, M.D.: Hello, and welcome to CURE®'s Educated Patient Sound Bites on metastatic uveal melanoma. I’m Dr. Marlana Orloff, an associate professor of medicine at Thomas Jefferson ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window So at AAO I gave ...
MADRID — The positive effect of the bispecific fusion protein tebentafusp on the overall survival of patients with uveal melanoma in the IMCgp100-202 study lasted through at least 36 months of ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorisation for tebentafusp (Kimmtrak; Immunocore), a novel ...
The FDA approved tebentafusp-tebn for the treatment of adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma. Tebentafusp-tebn (Kimmtrak, Immunocore) — the only FDA-approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback